Journal of Clinical Virology
Volume 35, Issue 2 , Pages 160-166 , February 2006

Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation

  • Beatrice Ludwig

      Affiliations

    • Institute for Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul Ehrlich-Str.40, D-60596 Frankfurt am Main, Germany
    • ,
  • Frank Bernhard Kraus

      Affiliations

    • Institute for Zoology, Martin-Luther-University Halle/Wittenberg, Hoher Weg 4, 06099 Halle (Saale), Germany
    • ,
  • Melanie Kipp

      Affiliations

    • Institute for Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul Ehrlich-Str.40, D-60596 Frankfurt am Main, Germany
    • ,
  • Wolfgang Preiser

      Affiliations

    • Institute for Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul Ehrlich-Str.40, D-60596 Frankfurt am Main, Germany
    • ,
  • Rainer Schwerdtfeger

      Affiliations

    • Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany
    • ,
  • Hans Wilhelm Doerr

      Affiliations

    • Institute for Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul Ehrlich-Str.40, D-60596 Frankfurt am Main, Germany
    • ,
  • Sigune Buxbaum

      Affiliations

    • Institute for Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul Ehrlich-Str.40, D-60596 Frankfurt am Main, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 69 6301 83062; fax: +49 69 6301 83061.

Received 19 January 2005 ,Revised 15 June 2005 ,Accepted 17 June 2005.

References 

  1. Alberola J, Tamarit A, Cardenoso L, Estelles F, Igual R, Navarro D. Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. J Med Virol. 2001;64:35–41
  2. Aubert G, Hassan-Walker AF, Madrigal JA, Emery VC, Morte C, Grace S, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis. 2001;184:955–963
  3. Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis. 1995;171:1115–1121
  4. Britt W, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccina virus-infected cells in analysis of the human neutralising antibody response. J Virol. 1990;64:1079–1085
  5. Broers AE, van Der HR, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240–2245
  6. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232–1240
  7. Deayton JR, Sabin CA, Britt WB, Jones IM, Wilson P, Johnson MA, et al. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS. 2002;16:2129–2135
  8. Eggers M, Radsak K, Enders G, Reschke M. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol. 2001;63:135–142
  9. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood. 1993;82:1672–1678
  10. Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:501–511
  11. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101:2686–2692
  12. Gönczöl E, de Taisne C, Hirka G, Berencsi K, Lin W, Paoletti E, et al. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine. 1991;9:631–637
  13. Graham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med. 1994;180:1273–1282
  14. Gratama JW, Cornelissen JJ. Diagnostic potential of tetramer-based monitoring of cytomegalovirus-specific CD8+ T lymphocytes in allogeneic stem cell transplantation. Clin Immunol. 2003;106:29–35
  15. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. BioDrugs. 2003;17:325–338
  16. Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98:1358–1364
  17. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–3067
  18. Jayaraman S, Heiligenhaus A, Rodriguez A, Soukiasian S, Dorf ME, Foster CS. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells. J Immunol. 1993;151:5777–5789
  19. Just-Nubling G, Korn S, Ludwig B, Stephan C, Doerr HW, Preiser W. Primary cytomegalovirus infection in an outpatient setting—laboratory markers and clinical aspects. Infection. 2003;31:318–323
  20. Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun. 1993;61:1069–1073
  21. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol. 2002;118:44–57
  22. Marshall G, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis. 1992;165:381–384
  23. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138–146
  24. Munoz I, Gutierrez A, Gimeno C, Farga A, Alberola J, Solano C, et al. Lack of association between the kinetics of human cytomegalovirus (HCMV) glygoprotein B and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J Med Virol. 2001;65:77–84
  25. Nomura LE, Walker JM, Maecker HT. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry. 2000;40:60–68
  26. Pass RF. Cytomegalovirus. In: 4th ed..  Knipe DM,  Howley PM editor. Fields virology. vol. 2:Philadelphia: Lippincott Williams and Wilkins; 2001;p. 2675–2705
  27. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis. 2001;32:596–603
  28. Preiser W, Buxbaum S, Fleckenstein C, Doerr HW. Measurement of CMV DNA levels and CMV-specific CD4+ lymphocyte counts in patient specimens: requirements for test quality and practicability in a routine diagnostic service. In:  Prösch S,  Cinatl J,  Scholz M editor. New aspects of CMV-related immunopathology. vol. 24:Basel: Monogr Virol. Karger; 2003;p. 133–148
  29. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother. 2000;45(Suppl. T3):35–43
  30. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–241
  31. Rothe M, Pepperl-Klindworth S, Lang D, Vornhagen R, Hinderer W, Weise K, et al. An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA. J Med Virol. 2001;65:719–729
  32. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis. 1998;178:1233–1243
  33. Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001;71:1287–1294
  34. Snydman DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis. 1990;12:839–848
  35. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica. 1999;84:71–79
  36. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods. 1998;212:89–98
  37. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12–18
  38. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277–279

PII: S1386-6532(05)00179-4

doi: 10.1016/j.jcv.2005.06.004

Journal of Clinical Virology
Volume 35, Issue 2 , Pages 160-166 , February 2006

Article Tools

* Image Usage & Resolution